Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,694
datasets available to search
ShareScore release 0.9.0
Dataset results
10,694 results for “carcinoma,”
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov study NCT03586973. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoi
ClinicalTrials.gov study NCT03945773. IPD Sharing: YES. Countries: 7. Publications: 1.
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov study NCT03783442. IPD Sharing: YES. Countries: 16. Publications: 2.
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
ClinicalTrials.gov study NCT02605967. IPD Sharing: YES. Countries: 7. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
ClinicalTrials.gov study NCT02872714. IPD Sharing: YES. Countries: 11. Publications: 2.
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04154943. IPD Sharing: YES. Countries: 3. Publications: 2.
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
ClinicalTrials.gov study NCT03339219. IPD Sharing: YES. Countries: 1. Publications: 2.
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
ClinicalTrials.gov study NCT01327053. IPD Sharing: YES. Countries: 12. Publications: 4.
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
ClinicalTrials.gov study NCT04472429. IPD Sharing: YES. Countries: 13. Publications: 2.
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
ClinicalTrials.gov study NCT01147822. IPD Sharing: YES. Countries: 3. Publications: 2.
Supplementary data for: Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression
Open the record for dataset details and reuse information.
Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma
Open the record for dataset details and reuse information.
The Clinical Significance of Serum p53 Antibody Levels in Patients with Oral Squamous Cell Carcinoma in Japanese Clinical Practice
<p>Supplementary Figure S1. Serum anti-p53 antibody titers in each clinical stage.<br> Supplementary Table S1. The change of Ap53Ab titer in patients with OSCC after surgery.</p>
The Influence of the Extremely Low Frequency Electromagnetic Field on Clear Cell Renal Carcinoma
<p>Abstract:</p> <p> </p> <p>The development of new technologies and industry is conducive to the increase in the number and variety of electromagnetic field (EMF) sources in our environment. The main sources of EMF are high-voltage lines, household appliances, audio/video devices, mobile phones, radio stations, and radar devices. In the growing use of electronic devices, scientists are increasingly interested in the effects of EMF on human health. Even though many studies on the effects of EMF have already been carried out, none of them has shown a significant effect on mammals, including humans. Moreover, it is not entirely clear how EMF influences cell behavior. The International Agency for Research on Cancer on May 31, 2011, classified PEM as a possible carcinogenic factor. This study aimed to investigate the effect of the electromagnetic field on morphological and functional changes in clear cell renal carcinoma. The research was carried out on in vitro cultures of four cell lines: HEK293, 786-O 769-P, and Caki1. The results of the research showed that the EMF of low frequency had a slight effect on the viability of cells. EMF, which induced cell arrest in the G1 phase, increased the number of early apoptotic cells and decreased the number of viable cells in the 786-O line. EMF did not affect the proliferation and viability of HEK293 cells. Extreme low-frequency EMF (ELF-EMF) also showed an inhibitory effect on the migration and metastatic properties of clear cell kidney cancer cells. Moreover, shortly after the end of ELF-EMF exposure, significant increases in ROS levels were observed in all tested cell lines. As part of the work, it was shown that low-frequency EMF shows an inhibitory effect on the proliferation of primary cancer cells, diminishing their migratory, invasive, and metastatic abilities. It also increases the apoptosis of cancer cells and the amount of reactive oxygen species. Based on the results of our research, we want to point up that the effect of ELF-EMF depends on a specific metabolic state or at a specific stage in the cell cycle of the cells under study.</p> <p> </p> <p> </p>
Leptomeningeal metastasis from Adrenocortical carcinoma: a case report
<p>Adrenocortical carcinoma (ACC) is an uncommon endocrine malignancy with limited treatment options. While overall 5-year survival rate in patients with ACC is 35%, the disease is often rapidly progressive with long-term survival in only 5% of patients. Although tumor stage, grade and excess hormonal activity predict unfavorable prognosis, additional biomarkers are needed to identify patients with aggressive disease.</p> <p>A 23-year-old woman presented with rapidly progressing signs and symptoms of Cushing's syndrome, with associated abdominal pain and fullness. Evaluation revealed a large left adrenal mass which had developed over 8 months. En bloc surgical resection was performed by an endocrine surgeon, and pathology revealed adrenocortical carcinoma with Ki67 of 60%. Despite adjuvant treatment with mitotane and etoposide-doxorubicin-carboplatin chemotherapy, the patient had rapid disease progression with metastatic spread to liver, lung, bone, brain and leptomeningies and she died eleven months after the initial diagnosis. Subsequent analysis of patient's tumor revealed mutations in TP53 and MEN1. RNA sequencing was compared against the The Cancer Genome Atlas data set and clustered with the high steroid, proliferative subtype, associated with the worst prognosis. The tumor also demonstrated a low BUB1B/PINK1 ratio as well as G0S2 hypermethylation, both predictive of very aggressive ACC.</p> <p>This case represents a subset of ACC characterized by rapid and fatal progression. Clinically available predictors as well as recently reported molecular signatures and biomarkers correlated with this tumor's aggressiveness, suggesting that development and validation of combinations of biomarkers may be useful in guiding personalized approaches to patients with ACC.</p>
Breast carcinoma histological images from the Department of Pathology, "Agios Pavlos" General Hospital of Thessaloniki, Greece
<p>This dataset contains cases of breast carcinoma histological specimens received at the Department of Pathology, “Agios Pavlos” General Hospital of Thessaloniki, Greece. The dataset consists of 300 annotated images of resolution 1280x960 corresponding to 21 different patients with invasive ductal carcinoma of the breast of grades 1-3 (grouped in the corresponding folders).</p> <p>More details about the dataset are presented in the paper: </p> <p>K. Dimitropoulos, P. Barmpoutis, C. Zioga, A. Kamas, K. Patsiaoura and N. Grammalidis, "Grading of invasive breast carcinoma through Grassmannian VLAD encoding", submitted for publication to PLOS ONE, 2017.</p>
Spatial mapping of the hepatocellular carcinoma landscape identifies unique intratumoural perivascular-immune neighbourhoods
<p>The uploaded data includes results from imaging mass cytometry (IMC) data collected from hepatocellular carcinoma patients. The associated publication can be found <a href="https://journals.lww.com/hepcomm/fulltext/2024/11010/spatial_mapping_of_the_hcc_landscape_identifies.11.aspx">here</a> (Marsh-Wakefield <em>et al.</em>, 2024, <em>Hepatology Communications</em>).</p> <p>The CSV file contains segmented cells from IMC data. This includes the Patient, ROI, and Group each cell is assigned. Marker signal intensities underwent arcsine transformation and were rescaled. The “simprof_cluster” column contains the final iteration of clustering following initial X-shift clustering.</p> <p>Notes on additional columns:</p> <ul> <li>“Sample” is barcoded such that the first three digits are the ablation number, followed by the region on the TMA, the group, and the patient. I.e., “[ablation.number]_[TMA.location]_[group]_[patient]”.</li> <li>“x” and “y” refer to the coordinates of samples.</li> <li>“Group” refers to the tissue type. Included non-tumour (NT), invasive margin (IM), and tumour (T) regions.</li> <li>The area for each ROI has been calculated (µm^2 and mm^2).</li> <li>“Batch” refers to TMA.</li> <li>In most cases each area from each patient has three ablation sites. Three samples have an extra ablation site due to technical difficulties during the ablation, and hence have a “split” sample.</li> </ul> <p>The PDF file contains patient information associated with the IMC data.</p> <p>DOI of dataset:</p> <p>10.5281/zenodo.10622397</p> <p>Any further questions can be addressed to Felix Marsh-Wakefield felix.marsh-wakefield@sydney.edu.au</p>
Characterization of the tumor-immune microenvironment in hepatocellular carcinoma by highly multiplexed imaging mass cytometry
<p>Imaging mass cytometry data of 54 HCC patients. </p> <ul> <li>DC_img_normalized: Preprocessed and normalized multistack .tiff images. Each stack represents one channel. Channel annotations are stored in the ICICohort_panel.csv file. ROIs are located in the tumor, interface and adjacent liver as indicated in the file name.</li> <li>DC_cellmasks: Masks identifying individual cells on the images.</li> <li>DC_stromamasks: Masks identifying stromal and parenchymal regions on the image.</li> <li>DCCohort_panel.csv: table containing channel information (metal tag and marker).</li> </ul> <p>Patient metadata may be found as supplementary table 2 of DOI <a href="https://doi.org/10.1136/gutjnl-2024-332837" target="_blank" rel="noopener noreferrer"> 10.1136/gutjnl-2024-332837 </a>.</p>
Gene expression landscape of cutaneous squamous cell carcinoma progression
<p>Data files associated with "Gene expression landscape of cutaneous squamous cell carcinoma progression" by Bencomo and Lee. </p><p>The README.md file has descriptions for each file.</p><p><strong>Funding support</strong>: This work was supported by a Scholar-Innovator Award from the Harrington Discovery Institute and a Discovery Boost grant from the American Cancer Society (CSL).</p>
NOVEL MOLECULAR TARGETS FOR HEPATOCELLULAR CARCINOMA
<p><strong>Abstract: </strong>Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing of potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T cell cross-reactivity with paired epitopes. These results provide novel HCC-specific Tumor-associated antigens (TAAs)TAAs for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8<sup>+</sup> T cells with superior anti-cancer efficacy.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.